Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Another key platform, GastroPlus, is a physiologically based pharmacokinetic modeling system used to simulate drug absorption and systemic exposure. These platforms support drug development programs ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email pr@fool.com Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...